Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 20.04.2026 1 Adv Ther 2 Am J Clin Pathol 1 Anal Chem 3 Ann Surg Oncol 1 Appl Biochem Biotechnol 1 Arkh Patol 1 Biochim Biophys Acta Mol Cell Res 1 Biol Direct 1 Biomark Res 1 Bladder Cancer 1 Br J Cancer 1 Cancer Cell 1 Cancer Res Commun 1 Cancers (Basel) 2 Cell Death Dis 1 Cell Death Discov 1 Clin Genitourin Cancer 1 Clin Lab 1 Curr Urol Rep 1 Ecotoxicol Environ Saf 1 Front Oncol 1 Genes Genomics 1 IEEE J Biomed Health Inform 1 Immunotherapy 1 Int J Mol Sci 1 Int J Nanomedicine 1 Int J Urol 1 iScience 1 J Cell Mol Med 1 J Clin Oncol 1 J Ethnopharmacol 1 J Nanobiotechnology 2 J Transl Med 1 JAMA Netw Open 1 Medicine (Baltimore) 1 Mod Pathol 1 Mol Biol Rep 1 Nat Rev Urol 1 Onco Targets Ther 1 Oncol Lett 1 Palliat Support Care 1 Patient Prefer Adherence 1 PLoS One 2 Scand J Urol 1 Sci Adv 3 Sci Rep 2 Transl Androl Urol 1 Transl Cancer Res 1 Transl Oncol 2 Urol Oncol 1 Urologia 1 World J Surg Oncol 1 Zhonghua Yi Xue Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Ther

1. KANESVARAN R, Giannatempo P, Filicevas A
   Empowering Patients: The Role of Shared Treatment Decision-Making in Advanced Bladder Cancer-A Podcast.
   Adv Ther. 2026 Apr 15. doi: 10.1007/s12325-026-03535.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

2. MOLNAR A, Montoya-Cerrillo D, Montgomery EA, Kryvenko ON, et al
   The ancillary role of D2-40 in demonstration of muscularis propria invasion vs desmoplastic reaction in invasive urothelial carcinoma of the bladder.
   Am J Clin Pathol. 2026;165:aqag025.
   PubMed         Abstract available
   
   
3. GUPTA S, Kosari F, Thapa P, Murphy SJ, et al
   Sarcomatoid urothelial carcinoma with constitutive PD-L1 overexpression.
   Am J Clin Pathol. 2026;165:aqag023.
   PubMed         Abstract available
   
   

   
   Anal Chem

4. BAO Q, Yoshioka T, Sato S, Goto S, et al
   Correlation-Based Morphometric Analysis Reveals Structural Remodeling of Platelet-Bound Circulating Tumor Cells in Urothelial Carcinoma.
   Anal Chem. 2026;98:10668-10675.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. YANG Y, Wu Y, Yang K, Song G, et al
   Preliminary Experience of Transurethral Thulium Laser En Bloc Resection of Paraganglioma of the Urinary Bladder.
   Ann Surg Oncol. 2026;33:4806-4811.
   PubMed         Abstract available
   
   
6. LI H, Mou Y, Liu Z, Yu C, et al
   Robotic Ureteroileal Bypass Repair for Post-Cystectomy Bricker Ureteroenteric Anastomotic Strictures: Stepwise Approach and Clinic Outcomes.
   Ann Surg Oncol. 2026;33:4850-4857.
   PubMed         Abstract available
   
   
7. LI C, Cheng C, Li S, Wang D, et al
   Integration of Node-RADS and Habitat Radiomics for Predicting Occult Nodal Metastasis in Bladder Cancer.
   Ann Surg Oncol. 2026 Apr 12. doi: 10.1245/s10434-026-19624.
   PubMed         Abstract available
   
   

   
   Appl Biochem Biotechnol

8. SUN X, Qi Q, Ding X, Wang X, et al
   The Tumor-Promoting Role of ADM in Bladder Cancer and its Mediated Mechanisms of Cell Death via PKR and STAT1.
   Appl Biochem Biotechnol. 2026 Apr 14. doi: 10.1007/s12010-026-05691.
   PubMed        
   
   

   
   Arkh Patol

9. SYCHEVA IN, Oleynikova NA
   [The features of cancer-associated fibroblasts as components of tumor stroma in bladder cancer].
   Arkh Patol. 2026;88:87-93.
   PubMed         Abstract available
   
   

   
   Biochim Biophys Acta Mol Cell Res

10. YAO K, Wang L, Wang J, Liu J, et al
    FTO-mediated m6A demethylation inhibits bladder cancer progression via decreasing EMG1 and reducing ribosome biosynthesis.
    Biochim Biophys Acta Mol Cell Res. 2026;1873:120147.
    PubMed         Abstract available
    
    

    
    Biol Direct

11. WANG Y, Gong S, Shen J, Liu G, et al
    Integrative analysis of myeloid cell signatures identifies a prognostic risk model and potential mechanisms in bladder cancer.
    Biol Direct. 2026 Apr 16. doi: 10.1186/s13062-026-00785.
    PubMed        
    
    

    
    Biomark Res

12. ANDRZEJCZAK A, Krajewski W, Jaskula E, Chorbinska J, et al
    Soluble immune checkpoints as diagnostic biomarkers in bladder cancer.
    Biomark Res. 2026;14:44.
    PubMed         Abstract available
    
    

    
    Bladder Cancer

13. MAI M, Tran V, Zhu A, Appiah D, et al
    Patterns of care and associated social determinants of health in the definitive treatment of localized muscle-invasive bladder cancer patients.
    Bladder Cancer. 2026;12:23523735261438727.
    PubMed         Abstract available
    
    

    
    Br J Cancer

14. TEKE K, Ozer C, Yaprak Bayrak B, Reyhancan IA, et al
    Boron neutron capture therapy (BNCT) for experimental bladder cancer: systemic or intravesical approach.
    Br J Cancer. 2026 Apr 17. doi: 10.1038/s41416-026-03418.
    PubMed         Abstract available
    
    

    
    Cancer Cell

15. MAHADEVAN KK, Kalluri R
    Tumor-restraining fibroblasts emerge after chemotherapy specifically in responders.
    Cancer Cell. 2026;44:708-709.
    PubMed         Abstract available
    
    

    
    Cancer Res Commun

16. ANDERSEN L, Lindskrog SV, Nordentoft I, Frydendahl A, et al
    Cell-Free DNA-Derived Immune Cell Ratios Uncover Cancer-Associated Systemic Changes.
    Cancer Res Commun. 2026;6:811-820.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

17. CANCERS EDITORIAL OFFICE
    Expression of Concern: Juengel et al. Mechanisms Behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro. Cancers 2019, 11, 777.
    Cancers (Basel). 2026;18:1077.
    PubMed         Abstract available
    
    

    
    Cell Death Dis

18. FAN X, Li Z, Gao Q, Huang P, et al
    TRIM28 orchestrates SUMO-ubiquitin crosstalk to stabilize PPARG and drive bladder cancer progression.
    Cell Death Dis. 2026 Apr 13. doi: 10.1038/s41419-026-08745.
    PubMed         Abstract available
    
    
19. HUI K, Gao Y, Huang J, Xu S, et al
    Correction: RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.
    Cell Death Dis. 2026;17:393.
    PubMed        
    
    

    
    Cell Death Discov

20. NIU S, Yang P, Yao Y, Tang X, et al
    NT5DC2 inhibits ferroptosis by stabilizing ACSL3 in bladder cancer.
    Cell Death Discov. 2026 Apr 14. doi: 10.1038/s41420-026-03091.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

21. MUSAEV A, Akpinar C, Ulgen TK, Erkmen S, et al
    Impact of Different Surveillance Intervals on Recurrence and Progression in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026;24:102543.
    PubMed         Abstract available
    
    

    
    Clin Lab

22. CHA JH, Kim KJ, Yun SG, Nam MH, et al
    Diagnostic Aspects of a Bacillus Calmette-Guerin (BCG) Infection Following Intravesical Treatment for Bladder Cancer.
    Clin Lab. 2026;72.
    PubMed         Abstract available
    
    

    
    Curr Urol Rep

23. ANGULO-LOZANO JC, Calvillo-Ramirez A, Noyola-Perez A, Cojuc-Konigsberg G, et al
    Unequal Access to Novel Systemic Therapies for Bladder Cancer: A Global Analysis of Clinical Trials of Immune Checkpoint Inhibitors and Antibody-Drug Conjugates.
    Curr Urol Rep. 2026;27:21.
    PubMed        
    
    

    
    Ecotoxicol Environ Saf

24. WANG J, Lu M, Qi N, Zhang M, et al
    Integrated machine learning and experimental validation reveal S6K2 as a key target of 6PPD-quinone in bladder cancer.
    Ecotoxicol Environ Saf. 2026;316:120085.
    PubMed         Abstract available
    
    

    
    Front Oncol

25. BAJDAK-RUSINEK K, Jankowska K, Sundararajan V, Sieron L, et al
    ESRP2 constrains EMT plasticity associated with ZEB1 expression in bladder cancer.
    Front Oncol. 2026;16:1764850.
    PubMed         Abstract available
    
    

    
    Genes Genomics

26. PARK C, Hwangbo H, Hong SH, Jeong HJ, et al
    5-Aminoimidazole-4-carboxamide riboside, an AMPK activator, enhances TRAIL-mediated apoptosis in human bladder cancer cells in a p38 MAPK-dependent manner.
    Genes Genomics. 2026 Apr 15. doi: 10.1007/s13258-026-01764.
    PubMed        
    
    

    
    IEEE J Biomed Health Inform

27. SONG Y, Yang Y, Qin J, Zhang Q, et al
    Transformer-Enhanced Joint Information Extraction Framework for Bladder Cancer Medical Dialogue Analysis.
    IEEE J Biomed Health Inform. 2026;PP.
    PubMed         Abstract available
    
    

    
    Immunotherapy

28. MENEGAT ALRS, Menegat BLRS, Braz LDG, Piccoli MVF, et al
    Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis.
    Immunotherapy. 2026;18:139-155.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

29. LIPKA U, Orywal K, Gudowska-Sawczuk M
    Matrix Metalloproteinases and Pro-Inflammatory Cytokines in Bladder Cancer: Diagnostic and Prognostic Perspectives: Narrative Review.
    Int J Mol Sci. 2026;27:3218.
    PubMed         Abstract available
    
    

    
    Int J Nanomedicine

30. LIU Y, Chen Y, Ye S, Hu J, et al
    Microwave-Responsive MnFe-Based Molybdenum Disulfide Nanoflowers for Enhanced Thermal-Dynamic-Chemo Synergistic Therapy in Bladder Cancer.
    Int J Nanomedicine. 2026;21:587614.
    PubMed         Abstract available
    
    

    
    Int J Urol

31. MUTA R, Fukushima H, Tanaka H, Numao N, et al
    Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study).
    Int J Urol. 2026;33:e70459.
    PubMed         Abstract available
    
    

    
    iScience

32. TONG H, Li T, Zhu J, Dou Q, et al
    RBM11 drives malignant progression of bladder cancer by regulating GNPDA1-PKM2 axis.
    iScience. 2026;29:115402.
    PubMed         Abstract available
    
    

    
    J Cell Mol Med

33. DENG H, Mi Y, Zhang L, Tan Y, et al
    ARIH2 Ubiquitination Regulates NUPR1 to Inhibit Ferroptosis in Bladder Cancer.
    J Cell Mol Med. 2026;30:e71147.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

34. 
    Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium.
    J Clin Oncol. 2026 Apr 17:JCO2502155. doi: 10.1200/JCO-25-02155.
    PubMed         Abstract available
    
    

    
    J Ethnopharmacol

35. HAN X, Dong S, Wang Y, Fang X, et al
    Grape seed proanthocyanidin extract suppresses bladder cancer by dual blockade of IMPDH1/2-mediated purine and pyrimidine nucleotide biosynthesis.
    J Ethnopharmacol. 2026 Apr 8:121663. doi: 10.1016/j.jep.2026.121663.
    PubMed         Abstract available
    
    

    
    J Nanobiotechnology

36. WEN J, Zhou B, Zhang H, Tang Y, et al
    Unlocking caspase-8 enables Pt(IV) to trigger robust caspase-3/GSDME-mediated pyroptosis via drug co-delivery in chemoresistant bladder cancer.
    J Nanobiotechnology. 2026 Apr 12. doi: 10.1186/s12951-026-04449.
    PubMed         Abstract available
    
    

    
    J Transl Med

37. CHEN Q, Chen T, Gan L, Lu Y, et al
    Mitophagy in bladder cancer: a double-edged sword in tumor progression and therapy.
    J Transl Med. 2026;24:523.
    PubMed         Abstract available
    
    
38. HAN Y, Zheng Z, Li X, Fan W, et al
    Letter to the editor: TGF-beta1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells.
    J Transl Med. 2026;24:489.
    PubMed        
    
    

    
    JAMA Netw Open

39. GIATSOGLOU M, Chatzistavrou D, Sopczynski JM, Feng G, et al
    Clinical Outcomes in Bacillus Calmette-Guerin-Exposed Non-Muscle-Invasive Bladder Cancer.
    JAMA Netw Open. 2026;9:e267470.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

40. HAO Y, Niu L, Shih YA, Gao P, et al
    A nurse-led cross-sectional latent profile analysis of fear of cancer recurrence in patients with non-muscle-invasive bladder cancer.
    Medicine (Baltimore). 2026;105:e48370.
    PubMed         Abstract available
    
    

    
    Mod Pathol

41. LI H, Argani P, Gross JM, Zhu J, et al
    Loss of Methylthioadenosine Phosphorylase (MTAP) Expression: A Potentially Useful Tool for Distinguishing Sarcomatoid Urothelial Carcinoma From Inflammatory Myofibroblastic Tumor.
    Mod Pathol. 2026;39:100980.
    PubMed         Abstract available
    
    

    
    Mol Biol Rep

42. MENBARI OSKOUIE I, Khatami F, Mesbah G, Baghdadabad LZ, et al
    Melatonin enhances the antitumor and immunomodulatory effects of Bacillus Calmette-Guerin immunotherapy in a murine bladder cancer model.
    Mol Biol Rep. 2026;53:600.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

43. ESTEBAN-VILLARRUBIA J, de Velasco G
    Targeting metastatic bladder cancer when money is an issue.
    Nat Rev Urol. 2026 Apr 13. doi: 10.1038/s41585-026-01142.
    PubMed        
    
    

    
    Onco Targets Ther

44. 
    Downregulation of Long Noncoding RNA TUG1 Inhibits Proliferation and Induces Apoptosis Through the TUG1/miR-142/ZEB2 Axis in Bladder Cancer Cells [Retraction].
    Onco Targets Ther. 2026;19:614701.
    PubMed         Abstract available
    
    

    
    Oncol Lett

45. ZHU YP, Bian XJ, Ye DW, Yao XD, et al
    [Expression of Concern] Pseudomonas aeruginosa-mannose-sensitive hema-gglutinin inhibits proliferation and induces apoptosis in a caspase-dependent manner in human bladder cancer cell lines.
    Oncol Lett. 2026;31:208.
    PubMed        
    
    

    
    Palliat Support Care

46. PUSTAKE M, Railkar A, Ganiyani MA, Khosla AA, et al
    Trends in preferred place of death among patients with bladder cancer in the United States, 2000 to 2020.
    Palliat Support Care. 2026;24:e108.
    PubMed         Abstract available
    
    

    
    Patient Prefer Adherence

47. ZHANG M, Zhou Y
    Bidirectional Longitudinal Associations Among Health-Related Quality of Life, Emotional Expressivity, and Readiness to Return to Work in Patients with Non-Muscle-Invasive Bladder Cancer Receiving Intravesical Therapy: A Three-Wave Cohort Study.
    Patient Prefer Adherence. 2026;20:594081.
    PubMed         Abstract available
    
    

    
    PLoS One

48. GUO D, Li X, Xu X, Chen X, et al
    The Physicochemical Synergy Effect of Nanosecond Pulsed Electric Fields (nsPEF) and cisplatin on reversing chemoresistance of bladder cancer.
    PLoS One. 2026;21:e0346699.
    PubMed         Abstract available
    
    

    
    Scand J Urol

49. BJORNSSON O, Geirsson G, Leifsson AS, Nikulasson SThorn, et al
    Early recurrence after primary TURBT for non-muscle-invasive bladder cancer in Iceland: the critical role of surgical quality.
    Scand J Urol. 2026;61:131-137.
    PubMed         Abstract available
    
    
50. MESINOVIC D, Bobjer J, Hagberg O, Aljabery F, et al
    Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer.
    Scand J Urol. 2026;61:127-130.
    PubMed         Abstract available
    
    

    
    Sci Adv

51. ZHAO C, Hou D, Wang K, Chen J, et al
    Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer.
    Sci Adv. 2026;12:eaeb9764.
    PubMed         Abstract available
    
    

    
    Sci Rep

52. WANG J, Liu H, Li K, Xie Z, et al
    Therapeutic potential of asparagus polysaccharide in bladder cancer treatment via modulation of PI3K/AKT/mTOR signaling.
    Sci Rep. 2026 Apr 15. doi: 10.1038/s41598-026-47595.
    PubMed         Abstract available
    
    
53. WANG L, Zhang J, Liu Y, Sun Y, et al
    Machine learning prediction of postoperative recurrence in bladder cancer using clinical and laboratory indicators.
    Sci Rep. 2026 Apr 15. doi: 10.1038/s41598-026-48493.
    PubMed        
    
    
54. ZHA J, Guo X, Liao W, Wu P, et al
    Inhibition of TRPC6 channel suppresses bladder cancer proliferation by disrupting store-operated calcium entry.
    Sci Rep. 2026 Apr 14. doi: 10.1038/s41598-026-45219.
    PubMed        
    
    

    
    Transl Androl Urol

55. OSKARSSON E, Johansson M, Liden O, Alamdari F, et al
    Comorbidity alterations between time for diagnosis and radical cystectomy in patients with muscle invasive bladder cancer undergoing neoadjuvant chemotherapy.
    Transl Androl Urol. 2026;15:77.
    PubMed         Abstract available
    
    
56. LIU Q, Zhou P, Tian D
    Identification of RNA processing-related gene-based bladder cancer subtypes for prognosis and immune landscape assessment.
    Transl Androl Urol. 2026;15:74.
    PubMed         Abstract available
    
    

    
    Transl Cancer Res

57. MENG H, Wang X, Liu P, Liu Q, et al
    Development and feasibility assessment of an automated, synthetic CT-guided plan selection system for bladder cancer adaptive radiotherapy: a retrospective pilot study.
    Transl Cancer Res. 2026;15:194.
    PubMed         Abstract available
    
    

    
    Transl Oncol

58. ZHU L, Liu Y, Lan J, Cai E, et al
    Identification of MYC co-expression gene: POLR3G is associated with cell senescence, immunotherapy, chemotherapy responses, and clinical prognosis in bladder cancer patients.
    Transl Oncol. 2026;68:102770.
    PubMed         Abstract available
    
    

    
    Urol Oncol

59. UYSAL D, Reible B, Wildner L, Steidler A, et al
    Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy.
    Urol Oncol. 2026 Apr 14:111095. doi: 10.1016/j.urolonc.2026.111095.
    PubMed         Abstract available
    
    
60. SCILIPOTI P, Zaurito P, Longoni M, Occhi A, et al
    The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
    Urol Oncol. 2026 Apr 11:111085. doi: 10.1016/j.urolonc.2026.111085.
    PubMed         Abstract available
    
    

    
    Urologia

61. PACINI P, Orecchia L, Asimakopoulos AD, Manfredi M, et al
    The role of Bladder EpiCheck((R)) test in predicting residual tumor after transurethral resection of bladder cancer: Results from a pilot study.
    Urologia. 2026 Apr 16:3915603261440213. doi: 10.1177/03915603261440213.
    PubMed         Abstract available
    
    

    
    World J Surg Oncol

62. PENG S, Liu Y, Huang P, Liu Q, et al
    MTHFD1L in muscle invasive bladder cancer: a multi-cohort study on prognosis and therapeutic response.
    World J Surg Oncol. 2026 Apr 14. doi: 10.1186/s12957-026-04346.
    PubMed         Abstract available
    
    

    
    Zhonghua Yi Xue Za Zhi

63. LIANG S, Qie YK, Jia KP, Bai YD, et al
    [Efficacy and safety of transvaginal assisted total intracavitary orthotopic neobladder surgery for female urothelial carcinoma of the bladder].
    Zhonghua Yi Xue Za Zhi. 2026;106:1484-1488.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum